VBI Vaccines Announces Sci-B-Vac®Phase 3 Study Meets Primary and Secondary Endpoints

Ontario Industry Updates
Written By Guest User

VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac®, the company’s trivalent hepatitis B (HBV) vaccine, and comparing safety and immunogenicity of Sci-B-Vac® to GlaxoSmithKline’s currently-marketed HBV vaccine, Engerix-B®. The Phase 3 study met both the primary and secondary endpoints.

Guest User
Previous

Fusion Pharmaceuticals receives investment commitment of up to US$20M
Next

Apply for the Canadian Technology Accelerator - Health Programs